Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Reduced versus standard dose apixaban for secondary prevention of cancer-associated venous thromboembolism: A systematic review and meta-analysis

Vasu Malhotra, Shreya Patel, Ardit Feinaj et al. Nov 03, 2025 pp. 4903-4903 10.1182/blood-2025-4903

Abstract INTRODUCTION Cancer-associated venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a...

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

Guneet Janda, Emmanuel Contreras Guzman, Michael Howe et al. Nov 03, 2025 pp. 924-924 10.1182/blood-2025-924

Abstract Introduction: Suboptimal response to therapy, early disease relapse, and limited long-term survival remain critical challenges in a...

Multi-omic single cell sequencing reveals discordant MRD and mechanisms of relapse in pediatric AML

Cheryl Peretz, Natalia Murad, Rula Gladden et al. Nov 03, 2025 pp. 348-348 10.1182/blood-2025-348

Abstract Introduction: Pediatric acute myeloid leukemia (AML) is a biologically heterogeneous disease. Prognosis is determined by risk of re...

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Nicholas Chornenki, Lisa Chodirker, Lee Mozessohn et al. Nov 03, 2025 pp. 964-964 10.1182/blood-2025-964

Abstract Background: Myelodysplastic syndrome (MDS) is a clonal hematologic disorder characterized by cytopenias and a risk of progression t...

A diagnostic hematology clinic pilot program: Increasing access and optimizing resources

Kathryn Knisely, Marina Beltrami Moreira, Roberta Azbell et al. Nov 03, 2025 pp. 597-597 10.1182/blood-2025-597

Abstract Introduction: The demand for specialized care in hematology is high and continues to rise. The complete blood count (CBC) is a wide...

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis

Wenbin Qian, Yun Liang Nov 03, 2025 pp. 7215-7215 10.1182/blood-2025-7215

Abstract Introduction: Brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, is approved for CD30-positive lymphomas. However, the...

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi et al. Nov 03, 2025 pp. 6376-6376 10.1182/blood-2025-6376

Abstract Background Bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and G-protein receptor class C, group 5, member...

VGA039 as a protein S-targeted hemostatic promoting monoclonal antibody, promotes in-vitro thrombin generation in plasma samples from subjects across a broad range of bleeding disorders, including von Willebrand disease, hemophilia A, hemophilia B and hemophilia C

Alina He, Paul Sims, Joanne Chan et al. Nov 03, 2025 pp. 1277-1277 10.1182/blood-2025-1277

Abstract Introduction: VGA039 is a fully human IgG4 monoclonal antibody that targets protein S (PS), a negative regulator of coagulation. VG...

Developing β-thalassemia mouse model by deleting hbb genes for therapeutic evaluation

Fengxing Gu, Ruili Lv, Saina Ma et al. Nov 03, 2025 pp. 4694-4694 10.1182/blood-2025-4694

Abstract Introduction: Thalassemia is a group of inherited hemolytic anemias caused by defective hemoglobin synthesis, leading to shortened...

In-hospital outcome of first-time acute chest syndrome in patients with preexisting pulmonary hypertension: A nationwide analysis 2016-2022

John Langley, Abdi Fite, Vera Jokic et al. Nov 03, 2025 pp. 6156-6156 10.1182/blood-2025-6156

Abstract Background: Although acute chest syndrome (ACS) and pulmonary hypertension (PH) are each recognized as risk fac...

Safety and efficacy of less differentiated CAR T-cell products in relapsed/refractory B-cell non-Hodgkin lymphomas: A meta-analysis

Gabriela Altizani, Paulo Zattar, Anna Albuquerque et al. Nov 03, 2025 pp. 5936-5936 10.1182/blood-2025-5936

Abstract Introduction: CAR T-cell therapy has revolutionized the treatment of B-cell malignancies, particularly in heavily pretreated patien...

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Wei Wang, Yueying Mao, Jing Ruan et al. Nov 03, 2025 pp. 5383-5383 10.1182/blood-2025-5383

Abstract Background: Emerging evidence suggests that triple-combination regimens incorporating Bruton tyrosine kinase (BTK) inhibitors, CD20...

Enhanced long-term outcomes with third-party unrelated cord blood co-infusion in a 122-patients cohort undergoing second allo-HSCT for AML in remission

Wei Zhao, Xingyu Cao, Yue Lu et al. Nov 03, 2025 pp. 4262-4262 10.1182/blood-2025-4262

Abstract Background While allo-HSCT is a curative approach for patients with hematologic malignancies, among them with relapse, graft failur...

Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)

Onyee Chan, Gabriel Marquez, Valentine Laizet et al. Nov 03, 2025 pp. 4611-4611 10.1182/blood-2025-4611

Abstract Introduction: First- and second-generation (1G and 2G) tyrosine kinase inhibitors (TKIs) have dramatically improved the outcomes of...

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

Irtiza Sheikh, Reeja Raj, Olayinka Okeleji et al. Nov 03, 2025 pp. 5156-5156 10.1182/blood-2025-5156

Abstract Background: BCL-2 inhibitors like venetoclax have demonstrated encouraging remission rates when combined with fludarabine, cytarabi...

CD4CAR T cells engage endogenous TCR to mediate antigen-independent cytotoxicity and distinct immune signatures.

Dharambir Kashyap, Malak Khalife, Lionel Apetoh et al. Nov 03, 2025 pp. 7627-7627 10.1182/blood-2025-7627

Abstract Background: Chimeric antigen receptor (CAR) T cell therapy enables targeted tumor cell killing through synthetic receptors that rec...

Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: Insights from real-world genomic data

Yu-Sung Chang, Feng-Ming Tien, Yu-Wen Wang et al. Nov 03, 2025 pp. 5249-5249 10.1182/blood-2025-5249

Abstract Introduction FLT3 mutations (FLT3MUT) are among the most frequently altered genes in acute myeloid leukemia (AML), and exhibit subs...

Front‑line ponatinib vs imatinib in newly diagnosed Philadelphia‑positive ALL: Systematic review and meta‑analysis of survival and deep molecular response

Kirti Arora, Preksha Singh, Prudence Lam et al. Nov 03, 2025 pp. 6862-6862 10.1182/blood-2025-6862

Abstract Front-Line Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia-Positive ALL: A Systematic Review and Meta-Analysis...

Lutetium-177 dotatate PRRT in GEP-NETs: Hematologic toxicity trends, recovery profiles, and discontinuation rates

Rana Megawer, Natasha Sheheryar, Mohamad Sonbol et al. Nov 03, 2025 pp. 6698-6698 10.1182/blood-2025-6698

Abstract Introduction: Lutetium-177 DOTATATE peptide receptor radionuclide therapy (PRRT) is an effective treatment for gastroenteropancreat...

Human intestinal acute graft-versus-host disease is governed by a subset of transition-like tissue-resident memory CD8+ T cells

Yiming Sun, Yutong Xue, Ruoyang Shao et al. Nov 03, 2025 pp. 2453-2453 10.1182/blood-2025-2453

Abstract Background: Tissue-resident memory T cells(TRM) have recently emerged as crucial cellular players for murine ac...

Earlier detection of transplant-associated thrombotic microangiopathy using harmonization criteria: A real-world comparative evaluation with conventional criteria

Seonghan Lee, Byung-Sik Cho, Ka Young Kim et al. Nov 03, 2025 pp. 5999-5999 10.1182/blood-2025-5999

Abstract Aim: Transplant-associated thrombotic microangiopathy (TA-TMA) is a frequently underrecognized complication of allogeneic hematopoi...

Development and validation of a new model for predicting occult cancer after unprovoked VTE and its comparative performance against riete and some scores

Abdulrahman Al Raizah, Nahla Wahby, Khalid Mohamed et al. Nov 03, 2025 pp. 4896-4896 10.1182/blood-2025-4896

Abstract Background: Venous thromboembolism (VTE) can be the first clinical manifestation of occult cancer. In our prior work, we externally...

The novel allosteric NEK7 inhibit ofirnoflast (HT-6184) reduces oxidized mitochondrial DNA in patients with low-risk myelodysplastic syndrome

Devan Bursey, Victoria Allgood, Andrea Groen et al. Nov 03, 2025 pp. 2093-2093 10.1182/blood-2025-2093

Abstract Background The progression of myelodysplastic syndromes (MDS) is driven by chronic sterile inflammation within the bone marrow micr...

Tet2-associated inflammatory signaling alters healthy hematopoiesis with clonal expansion

Alana Franceski, Francesca Luca, Paran Goel et al. Nov 03, 2025 pp. 4953-4953 10.1182/blood-2025-4953

Abstract Age-related clonal hematopoiesis (CH) is often driven by mutations in epigenetic regulators such as TET2. These mutations in epigen...

IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction

Carli Stewart, Mehrdad Hefazi Torghabeh, Makena Rodriguez et al. Nov 03, 2025 pp. 2338-2338 10.1182/blood-2025-2338

Abstract Recent studies have highlighted the important but pleiotropic role of IL-4 in response to chimeric antigen receptor T (CART) cell t...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page